Intervacc is trading 3.09% down now at €0.09, after no confirmed company-specific catalyst was identified for August 14, 2026.
- The latest notable announcement was a July 30 EMA application seeking 12-month Strangvac immunity.
- Second-quarter results are scheduled for August 20.
- Broader markets were modestly mixed-to-positive and do not clearly explain the decline; coverage remains limited and the cause is uncertain.